Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial

Table 5 Cost-effectiveness ratios

	Group	Total cost	Eradication rates	CER
ITT	V1	57.46	84.4%	0.68
	V2	60.58	84.4%	0.72
	V3	70.27	84.4%	0.83
PP	V1	57.46	88.4%	0.65
	V2	60.58	92.7%	0.65
	V3	70.27	88.4%	0.79

ISSN: 1471-230X